复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期患者的疗效及安全性研究

来源期刊：广州医药 | 1177-1182 发布时间：2024-11-05 收稿时间：2025/11/13 18:44:26 阅读量：46

作者：: 刘丽,

张明,

任建兵,

米奇珍,

闫有鹏,

关键词：: 复方甘草口服液泼尼松特发性肺间质纤维化急性加重期不良反应炎症因子; compound licorice oral liquid prednisone idiopathic pulmonary interstitial fibrosis acute exacerbation period adverse reactions inflammatory factors

DOI：: 10.20223/j.cnki.1000-8535.2024.10.013

收稿时间：: 2024-02-08
修订日期：
接收日期：
引用总数：: 3

目的探讨复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期患者的疗效。方法选取张掖市第二人民医院2020年1月—2023年10月收治的128例特发性肺间质纤维化急性加重期患者,应用随机数字表法分为两组,每组各64例。对照组采取泼尼松治疗,观察组采取复方甘草口服液联合泼尼松治疗。对比其临床疗效,治疗前后血清肺纤维化指标及炎症因子水平,最后对比其不良反应发生率。结果观察组总有效率93.75%,高于对照组的79.69%（χ²=5.490,P=0.019）;治疗前两组层黏连蛋白（LN）、Ⅲ型前胶原肽（PC-Ⅲ）、透明质酸（HA）对比差异无统计学意义（P>0.05）,治疗后两组患者LN、PC-Ⅲ、HA均降低,观察组[（89.25±7.61）μg/L;（68.33±7.68）mg/L;（81.53±8.54）μg/L]低于对照组[（96.17±8.34）μg/L;（75.68±8.25）mg/L;（95.68±9.25）μg/L],对比差异有统计学意义（t₁=4.903,P₁<0.001;t₂=5.217,P₂<0.001;t₃=8.992,P₃<0.001）;治疗前两组患者肿瘤坏死因子-α（TNF-α）、白细胞介素-4（IL-4）、IL-10、转化生长因子（TGF-β1）对比差异无统计学意义（P>0.05）,治疗后两组TNF-α、IL-4、IL-10、TGF-β1水平降低,观察组[（61.94±8.24）ng/L;（4.43±1.17）ng/mL;（65.49±13.24）g/L;（114.73±13.12）pg/mL]低于对照组[（75.52±9.43）ng/L;（6.31±1.28）ng/mL;（79.27±9.38）g/L;（147.76±15.46）pg/mL],对比差异有统计学意义（t₁=8.675,P₁<0.001;t₂=8.673,P₂<0.001;t₃=6.794,P₃<0.001;t₄=13.032,P₄<0.001）;两组不良反应发生率对比差异无统计学意义（7.81% vs 6.25%,χ²=0.120,P=0.730）。结论复方甘草口服液联合泼尼松治疗特发性肺间质纤维化急性加重期疗效显著,可辅助延缓患者肺纤维化发展进程,减轻机体炎症反应,安全性较高。

Objective To investigate the efficacy of compound licorice oral liquid combined with prednisone in patients with acute exacerbations of idiopathic pulmonary interstitial fibrosis. Methods A total of 128 patients with acute exacerbation of idiopathic pulmonary interstitial fibrosis admitted to Zhangye Second People's Hospital from January 2020 to October 2023 were divided into two groups by random number table method,with 64 patients in each group．The control group received prednisone treatment,while the observation group received compound licorice oral liquid combined with prednisone treatment．Compare its clinical efficacy,serum pulmonary fibrosis indicators and inflammatory factor levels before and after treatment,and finally compare its incidence of adverse reactions. Results The total response rate in the observation group was 93.75%,which was higher than the 79.69% in the control group（χ²=5.490,P=0.019）．There was no difference between the two groups of LN,PC-III,and HA（P>0.05）,LN,PC-III and HA were decreased in both groups,while the observation group[（89.25±7.61）μg/L;（68.33±7.68）mg/L;（81.53±8.54）μg/L] was lower than the control group[（96.17±8.34）μg/L;（75.68±8.25）mg/L;（95.68±9.25）μg/L],the contrast difference was statistically significant（t₁=4.903,P₁<0.001;t₂=5.217,P₂<0.001;t₃=8.992,P₃<0.001）．There was no difference in TNF-α,IL-4,IL-10,and TGF-β1 between the two groups before treatment（P>0.05）,lower levels of TNF-α,IL-4,IL-10,and TGF-β1 in the two patient groups after treatment,the observation group[（61.94±8.24）ng/L;（4.43±1.17）ng/mL;（65.49±13.24）g/L;（114.73±13.12）pg/mL] was lower than the control group[（75.52±9.43）ng/L;（6.31±1.28）ng/mL;（79.27±9.38）g/L;（147.76±15.46）pg/mL],the contrast difference was statistically significant（t₁=8.675,P₁<0.001;t₂=8.673,P₂<0.001;t₃=6.794,P₃<0.001;t₄=13.032,P₄<0.001）．There was no difference in the incidence of adverse effects between the two groups（7.81% vs 6.25%,χ²=120,P=0.730）. Conclusions The combination of compound licorice oral liquid and prednisone has a significant therapeutic effect on the acute exacerbation of idiopathic pulmonary interstitial fibrosis．It can assist in delaying the progression of pulmonary fibrosis in patients,reducing the body's inflammatory response,and has high safety．

1、[25] 冯碧阳,陈黎明.复方甘草片引起低血钾并发电交感风暴致病人反复晕厥1例报道[J].中西医结合心脑血管病杂志,2023,21(21):4043-4046.

2、[24] 刘薇,张玲,鲍洁,等.特发性肺间质纤维化患者预后不良的影响因素及预测价值[J].川北医学院学报,2022,37(4):426-429.

3、[23] 康冬梅,高勇,马继芳,等.特发性肺间质纤维化并发肺气肿的风险模型构建与评价[J].疑难病杂志,2022,21(12):1236-1241.

4、陈熔,王旭,舒静,等.特发性肺间质纤维化急性加重患者呼吸道微生态成分与不良预后的关系[J].疑难病杂志,2022,21(11):1141-1146.

5、魏祎,刘超,齐鸣,等.岩白菜素通过调控NF-κB/NLRP3通路和代谢对特发性肺间质纤维化小鼠的影响[J].中成药,2023,45(1):62-69.

6、焦欢,李龙.炎性指标与特发性肺间质纤维化并发呼吸衰竭的相关性分析[J].解放军医学杂志,2023,48(3):298-303.

7、魏秀丽,张传津,刘道中,等.UPLC-PDA联合UPLC-MS/MS法确证一批标称杨树花口服液中非法添加物甘草酸[J].中国兽药杂志,2023,57(10):47-53.

8、肖琼华,姚婷,吴琼,等.基于倾向性评分匹配法的祛痹化纤方治疗特发性肺间质纤维化疗效评价[J].辽宁中医杂志,2023,50(3):145-148.

9、赵海鹏,齐衍超,祁立新,等.市售复方甘草片的质量评价[J].中国现代应用药学,2022,39(13):1737-1743.

10、顾一丹,任允琰,章朱峰,等.基于网络药理学与分子对接探索人参-五味子配伍治疗特发性肺间质纤维化的分子机制[J].山东科学,2022,35(1):28-36.

11、魏祎,齐鸣,黄丽羽,等.岩白菜素治疗特发性肺间质纤维化的研究[J].医学研究生学报,2022,35(5):493-498.

12、杨天舒,张晓梅,李睿,等.姜良铎从状态论治特发性肺间质纤维化慢性发热[J].中华中医药杂志,2023,38(6):2648-2651.

13、李彬,别志欣,李元明,等.CT引导下经皮穿刺活检同步微波消融治疗特发性肺间质纤维化合并Ⅰ期非小细胞肺癌[J].中国介入影像与治疗学,2023,20(6):325-329.

14、 PAUCHET A,CHAUSSAVOINE A,PAIRON J C,et al.Idiopathic pulmonary fibrosis:What do we know about the role of occupational and environmental determinants?A systematic literature review and Meta-Analysis[J].J Toxicol Environ Health B Crit Rev,2022,25(7):372-392.

15、赵稳,王延生,周霞,等.肺纤维化急性加重患者短期内死亡危险因素分析[J].广州医药,2020,51(5):1-4.

16、 KARUGA F F,KACZMARSKI P,SZMYD B,et al.The association between idiopathic pulmonary fibrosis and obstructive sleep apnea:A systematic review and Meta-Analysis[J].J Clin Med,2022,11(17):5008.

17、 PETNAK T,LERTJITBANJONG P,THONGPRAYOON C,et al.Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis:A systematic review and Meta-Analysis[J].Chest,2021,160(5):1751-1763.

18、于娜,周家为,李霞,等.成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读[J].中国现代医学杂志,2023,33(14):1-8.

19、刘春明,张洪,李一鸣.Fleischner学会关于特发性肺纤维化诊断标准的白皮书解读[J].国际医学放射学杂志,2018,41(6):653-657.

20、柯月娇. 近5年医院制剂复方甘草口服溶液质量回顾分析[J].安徽医药,2022,26(1):205-208.

21、 PITRE T,MAH J,HELMECZI W,et al.Medical treatments for idiopathic pulmonary fibrosis:a systematic review and network meta-analysis[J].Thorax,2022,77(12):1243-1250.

22、 FINNERTY J P,PONNUSWAMY A,DUTTA P,et al.Efficacy of antifibrotic drugs,nintedanib and pirfenidone,in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis(IPF)and non-IPF:a systematic review and meta-analysis[J].BMC Pulm Med,2021,21(1):411.

23、 GHAZIPURA M,MAMMEN M J,BISSELL B D,et al.Pirfenidone in Progressive Pulmonary Fibrosis:A systematic review and Meta-Analysis[J].Ann Am Thorac Soc,2022,19(6):1030-1039.

24、 ZHENG Q,COX I A,CAMPBELL J A,et al.Mortality and survival in idiopathic pulmonary fibrosis:A systematic review and meta-analysis[J].ERJ Open Res,2022,8(1):00591-2021.

1、张志超,周贤梅.特发性肺纤维化的中医治疗研究进展[J].大医生,2025,10(07):132-136.

2、孙晓波,张明慧,张语琪,等.基于数据挖掘联合虚拟计算探讨中药复方治疗感染性肺炎的关键药效物质及作用机制[J].药物评价研究,2025,48(08):2164-2176.

3、邱念念,朱晓龙.沙参麦冬汤合桂枝茯苓丸加减治疗特发性肺间质纤维化的效果观察[J].内蒙古中医药,2025,44(09):62-63.DOI:10.16040/j.cnki.cn15-1101.2025.09.049.